Yahoo
NSE - Delayed Quote INR

Sun Pharmaceutical Industries Limited (SUNPHARMA.NS)

1,777.70 +16.70 (+0.95%)
At close: October 30 at 3:28:16 PM GMT+5:30
SUNPHARMA.NS Q2 2027 earnings call
Replay the call for the latest insights.
Chart Range Bar
Loading chart for SUNPHARMA.NS
  • Previous Close 1,761.00
  • Open 1,769.00
  • Bid --
  • Ask --
  • Day's Range 1,766.20 - 1,855.00
  • 52 Week Range 1,583.70 - 2,046.90
  • Volume 5,125,487
  • Avg. Volume 1,658,368
  • Market Cap (intraday) 4.265T
  • Beta (5Y Monthly) 0.14
  • PE Ratio (TTM) 38.90
  • EPS (TTM) 45.70
  • Earnings Date (est.) Jan 28, 2027
  • Forward Dividend & Yield 16.00 (0.90%)
  • Ex-Dividend Date Jul 7, 2026
  • 1y Target Est 2,174.34

Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, dental, and nutritionals. It also provides generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; specialty medications; antiretrovirals medications; and over-the-counter products, such as vitamins, analgesics, digestives, and lifestyle. In addition, the company offers generics and APIs for anti-cancers, peptides, steroids, sex hormones, immunosuppressant drugs, and controlled substances. Sun Pharmaceutical Industries Limited was founded in 1983 and is headquartered in Mumbai, India.

sunpharma.com

47,000

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

SUNPHARMA.NS
4.32%
S&P BSE SENSEX (^BSESN)
12.63%

1-Year Return

SUNPHARMA.NS
5.32%
S&P BSE SENSEX (^BSESN)
11.78%

3-Year Return

SUNPHARMA.NS
63.81%
S&P BSE SENSEX (^BSESN)
16.14%

5-Year Return

SUNPHARMA.NS
134.93%
S&P BSE SENSEX (^BSESN)
25.55%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY27
Revenue 161.99B
Earnings 19.89B
Profit Margin 12.28%

Q3

FY26

Q4

FY26

Q1

FY27

Q2

FY27

0
50B
100B
150B
14.0%
16.0%
18.0%
20.0%

Analyst Insights

View More

Analyst Price Targets

1,830.00
2,174.34 Average
1,777.70 Current
2,400.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    17.79%

  • Return on Assets (ttm)

    8.20%

  • Return on Equity (ttm)

    13.10%

  • Revenue (ttm)

    616.31B

  • Net Income Avi to Common (ttm)

    109.66B

  • Diluted EPS (ttm)

    45.70

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    335.7B

  • Total Debt/Equity (mrq)

    3.62%

  • Levered Free Cash Flow (ttm)

    75.43B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: